IDENIX PHARM (NASDAQ:IDIX)
1.84
+0.01 (0.55%)
| IDENIX PHARM (NASDAQ:IDIX) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $1.83 | 52 Week High | $6.82 | ||
| Open | $1.81 | 52 Week Low | $1.81 | ||
| Day High | $1.87 | P/E | N/A | ||
| Day Low | $1.81 | EPS | $-0.93 | ||
| Volume | 90,401 | ||||
| More IDIX Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| LVS | 3 | NVTL | 3 |
| SXE | 3 | TSRA | 3 |
| GNW | 3 | BARE | 3 |
| NANO | 3 | CEC | 3 |
| JDAS | 3 | AXTI | 3 |
| GFIG | 3 | APKT | 2 |
Entities who have mentioned IDIX
- Deutsche Bank | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- After-Hours Movers | View Related Stories »
- StreetInsider.com Morning Movers | View Related Stories »
- UBS | View Related Stories »
- Bankruptcy | View Related Stories »
- JMP Securities | View Related Stories »
- Morningstar, Inc. | View Related Stories »
- Trading Radar | View Related Stories »
- Chrysler LLC | View Related Stories »
- Susquehanna International Group of Companies | View Related Stories »
- ThinkPanmure | View Related Stories »
- Goldman Sachs | View Related Stories »
- Thomas Weisel Partners Group | View Related Stories »
- ThinkEquity | View Related Stories »
- Morgan Stanley | View Related Stories »
- Standard & Poor's | View Related Stories »
View All Major News StreetInsider.com Major News for IDIX
- Idenix Pharmaceuticals (IDIX) Tops Q3 EPS by 6c; Retains Worldwide Rights to Develop and Commercialize IDX184
- Idenix Pharmaceuticals (IDIX) Misses Q2 View By 3c
- Idenix Pharma (IDIX) Reports Better-Than Expected Q4 Loss of $0.25
View All ReportsStreetInsider.com Reports on IDIX
- Caris & Co Downgrades Idenix Pharmaceuticals (IDIX) to Above Average
- Morning Movers 10/30: PVFC, WPTE, CNXT, HPOL, TVL, MSTR Higher; NVTL, GFIG, TSRA, GGC, IDIX Lower
- Idenix (IDIX) Announces Presentations of IDx184 at AASLD in Boston
- After-Hours Movers 10/29: AXTI, ISSI, APKT, GNW, CEC, CSA, LVS Higher; IDIX, NVTL, TSRA, CRDC Lower
- Idenix Pharmaceuticals (IDIX) Tops Q3 EPS by 6c; Retains Worldwide Rights to Develop and Commercialize IDX184
View All Press ReleasesCompany Press Releases on IDIX
- Idenix Pharmaceuticals Initiates Phase II Clinical Trial of IDX184 in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
- Idenix Pharmaceuticals Presents Data on IDX184 for the Treatment of Hepatitis C Virus (HCV)
- Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV
- Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2009 Financial Results
- Idenix Pharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare Conference
StreetInsider Reports on IDIX by Category
View All BlogsBlogs on IDIX
- Biotech Discounts Galore
- Analyst upgrades, downgrades and initiations: CIEN, DLTR, EXPE, IBM, ZION ...
- Analyst upgrades, downgrades and initiations: CLX, ED, JBHT, HMC, PCG ...
- Ugly Stock Stats from an Ugly Bear
- Idenix Pharmaceuticals, Inc. Q4 2008 Earnings Call Transcript
View All FilingsSEC Filings on IDIX
- Form 4 IDENIX PHARMACEUTICALS For: Nov 11 Filed by: Standring David
- Form 10-Q IDENIX PHARMACEUTICALS For: Sep 30
- Form 8-K IDENIX PHARMACEUTICALS For: Oct 29
Comments on IDIX
No comments are currently available.
